How vaccine economics impacts Africa

In a joint report, Allianz Research and Euler Hermes say the recent breakthroughs in vaccine development will supercharge global growth this year, but short-term headwinds and a complete recovery in 2022 will create transition risks. They also note that despite the hurdles on the demand and supply sides, they expect vaccine rollout to vulnerable populations to be completed by mid-2021. Ludovic Subran, Chief Economist at Allianz joins CNBC Africa for more.

Fri, 12 Feb 2021 12:13:19 GMT
Sign Up for Our Newsletter Daily Update
Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent.
Get this delivered to your inbox, and more info about about our products and services. By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.